New Hope for a Deadly Childhood Brain Cancer
Diffuse midline glioma (DMG) is an aggressive childhood brain cancer that infiltrates healthy brain tissue, often growing within the brainstem—a region that regulates breathing, heart rate, and swallowing. Surgical removal is extremely dangerous or impossible, and children diagnosed with the disease almost always die within a year. Conventional treatments have long struggled against this devastating diagnosis.
Now, scientists at the University of California, San Francisco (UCSF) have delivered promising preclinical results: an experimental immune cell therapy called B-SYNC completely eliminated tumors in every mouse tested across two DMG models. The study was published October 28 in Science Translational Medicine.
What Is B-SYNC Therapy?
CAR-T cell therapy is a form of cancer immunotherapy that genetically modifies a patient's own T cells to produce special receptors that recognize proteins on cancer cells, then returns them to the body to attack the disease. However, conventional CAR-T therapies have not successfully controlled brain tumors like DMG.
B-SYNC's innovation lies in a molecular switch. Researchers equipped T cells with a synthetic sensor called synNotch that detects brevican, a protein widely distributed throughout the brain. Only when T cells enter the brain and encounter brevican do they trigger production of CAR receptors targeting EphA2 or IL13Rα2—two proteins found on many brain tumor cells.
- Precise targeting: CAR receptors are produced only in the brain, reducing systemic side effects
- Broad applicability: Does not depend on a specific mutation, potentially covering more patients
- Durable protection: Nearly seven weeks after treatment, mice still rejected reintroduced cancer cells
Tumors Disappear in Mouse Experiments
Using intracerebroventricular (ICV) injection to deliver B-SYNC CAR-T cells directly into the brain's fluid-filled ventricles, researchers achieved complete tumor clearance in every treated mouse across two human DMG models. Conventional CAR-T cells, tested for comparison, again failed to control the cancer.
Remarkably, nearly seven weeks after treatment, every animal previously treated with B-SYNC rejected a second introduction of DMG cells. Researchers suggest that restricting CAR production to the brain may prevent T cell exhaustion—a condition in which prolonged stimulation gradually weakens immune cell function.
"We didn't expect B-SYNC CAR-T cells to necessarily persist," said Senthilnath Lakshmanachetty, PhD, the study's first author. "But they are still patrolling for cancer over 70 days out—and they're still very functional."
Preparing for Human Clinical Trials
The UCSF team is working with clinical oncologists to bring B-SYNC into human trials, potentially beginning as early as April 2027. The first study will evaluate the therapy in children and young adults with brain tumors, investigating different combinations of intravenous and intracerebroventricular delivery.
"Diffuse midline glioma is a heartbreaking diagnosis for patients and their families," said Sabine Mueller, MD, PhD, director of the UCSF Pediatric Brain Tumor Center. "This preclinical data is very promising. We are incredibly excited to bring this therapy to the children and young adults we care for."
Everyday Health Monitoring Matters Too
While this breakthrough research offers new hope for brain tumor patients, daily health monitoring remains essential. Regularly tracking body metrics and paying attention to sleep quality and chronic disease risk are important steps in disease prevention. The Little Tree Health App can sync with Apple Health to track relevant indicators, helping you stay on top of your health and providing reference data for informed medical decisions.